ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,321.41
0.25%
Dow Jones
39,872.99
0.17%
US Dollar vs MXN
16.6339
0.48%
Brent Oil
82.75
-0.93%
Bitcoin
69,476.08
-2.76%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Nabriva Therapeutics PLC (NBRV)

  7. Nabriva Therapeutics PLC (NBRV) Noticias

NBRV

Nabriva Therapeutics (NBRV)

Nabriva Therapeutics PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NBRV
FechaHoraFuenteTítuloSímboloCompañía
25/10/202312:43Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:NBRVNabriva Therapeutics PLC
24/10/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NBRVNabriva Therapeutics PLC
19/10/202320:01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NBRVNabriva Therapeutics PLC
19/10/202319:22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:NBRVNabriva Therapeutics PLC
31/07/202307:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBRVNabriva Therapeutics PLC
10/07/202316:49Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NBRVNabriva Therapeutics PLC
10/07/202315:01GlobeNewswire Inc.Arbutus Appoints Two New ExecutivesNASDAQ:NBRVNabriva Therapeutics PLC
01/06/202315:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
22/05/202315:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NBRVNabriva Therapeutics PLC
15/05/202316:25Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:NBRVNabriva Therapeutics PLC
31/03/202315:30Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:NBRVNabriva Therapeutics PLC
10/01/202316:59Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
06/01/202306:01GlobeNewswire Inc.Nabriva Therapeutics Provides Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
29/11/202205:30TipRanksAnalysts Conflicted on These Healthcare Names: Nabriva (NBRV), Vir Biotechnology (VIR) and Greenwich LifeSciences (GLSI)NASDAQ:NBRVNabriva Therapeutics PLC
28/11/202206:01GlobeNewswire Inc.Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNASDAQ:NBRVNabriva Therapeutics PLC
10/11/202215:01GlobeNewswire Inc.Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
07/11/202206:01GlobeNewswire Inc.Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022NASDAQ:NBRVNabriva Therapeutics PLC
15/09/202206:01GlobeNewswire Inc.Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock SplitNASDAQ:NBRVNabriva Therapeutics PLC
06/09/202206:01GlobeNewswire Inc.Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:NBRVNabriva Therapeutics PLC
12/08/202205:36TipRanksH.C. Wainwright Remains a Hold on Nabriva (NBRV)NASDAQ:NBRVNabriva Therapeutics PLC
11/08/202206:01GlobeNewswire Inc.Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNASDAQ:NBRVNabriva Therapeutics PLC
03/08/202215:01GlobeNewswire Inc.Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
20/07/202215:05GlobeNewswire Inc.Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022NASDAQ:NBRVNabriva Therapeutics PLC
18/07/202208:56Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:NBRVNabriva Therapeutics PLC
18/07/202206:01GlobeNewswire Inc.Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim PharmaceuticalsNASDAQ:NBRVNabriva Therapeutics PLC
29/06/202215:23Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NBRVNabriva Therapeutics PLC
13/05/202206:01GlobeNewswire Inc.Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:NBRVNabriva Therapeutics PLC
05/05/202215:01GlobeNewswire Inc.Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
05/05/202206:01GlobeNewswire Inc.Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026NASDAQ:NBRVNabriva Therapeutics PLC
02/05/202215:05GlobeNewswire Inc.Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022NASDAQ:NBRVNabriva Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:NBRV

Su Consulta Reciente

NASDAQ
GOOGL
Alphabet
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
PM
XAUUSD
Gold vs US Dollar
COIN
SOLUSD
Solana
USOTC
BNPQY
BNP Paribas (QX)
USOTC
ADDYY
Adidas (QX)
AMEX
XLV
Health Care Select Sector
SPI
SP500
S&P 500
FX
EURUSD
Euro vs US Dollar
NYSE
MRK
Merck
NASDAQ
TSLA
Tesla
NYSE
MCD
McDonalds
NYSE
BAC
Bank of America
CCOM
US30
US 30
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados